Another variant vaccine, another potential risk
With the availability of the latest Pfizer (COMIRNATY®) Omicron XBB.1.5 vaccine, indicated for 12 years and over, there may be potential for selection or administration
With the availability of the latest Pfizer (COMIRNATY®) Omicron XBB.1.5 vaccine, indicated for 12 years and over, there may be potential for selection or administration
The recent availability of the Moderna Spikevax Bivalent Booster Vaccine has seen a rise in the number of vaccine-related calls and incident reports to PDL.
The recent surge in demand for influenza vaccines has also seen a rise in the number of vaccine-related calls and incident reports to PDL. This
As winter approaches, pharmacies will be very busy providing vaccinations against influenza (flu) as well as administering COVID-19 fourth doses (winter doses) or boosters. As
The ATAGI approval of Moderna Spikevax for the primary vaccination of children 6-11 years provides more options for families and pharmacists. Read the ATAGI statement.
The approval of the Pfizer Comirnaty Orange Cap (5-11 years) COVID-19 vaccine to be administered by pharmacists from 10 January 2022 offers opportunities and challenges for pharmacists. PDL encourages pharmacists to prepare for this
Vaccinating pharmacists take note… The Moderna Spikevax vaccine has been approved as a booster dose over the weekend with a different dose volume to the primary
The PDL Professional Officers have noted a recent reduction in the number of calls about the COVID-19 vaccination service. This is pleasing and a likely
PDL recognises the extraordinary efforts that pharmacists have made to provide COVID-19 vaccines to more than one million patients. It is very pleasing to report
The PDL Professional Officers continue to assist pharmacists with enquiries and incidents involving COVID-19 vaccines. Recent calls and reports have identified several consistent themes in